Literature DB >> 11304069

Wernicke-Korsakoff syndrome in head injury: a missed insult.

R K Ferguson1, I N Soryal, B Pentland.   

Abstract

A survey of the use of thiamine in patients at risk from Wernicke-Korsakoff syndrome (WKS) in Scottish specialist neurosurgical units, and a 2-year retrospective study of 218 at-risk patients admitted to a regional neurosurgical unit with a head injury were undertaken. Although responses to the survey indicated otherwise, the study revealed that there was no consistent practice regarding thiamine administration. Overall, 20.6% of patients received thiamine, with an alcohol history being the only factor correlating with thiamine administration. Of known alcoholics and heavy drinkers, 56.1% and 26.2% respectively received thiamine as in-patients; 44.5% of patients received additional carbohydrate loads in the form of i.v. dextrose or parenteral nutrition, but only 28.9% of these received thiamine as well. Although the actual thiamine status of these patients was not known, given the difficulties of diagnosing WKS in the presence of a head injury, the conclusion is that written protocols are needed in units to ensure that head injury patients at risk of WKS receive appropriate thiamine treatment or prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11304069     DOI: 10.1093/alcalc/35.supplement_1.16

Source DB:  PubMed          Journal:  Alcohol Alcohol Suppl        ISSN: 1358-6173


  2 in total

1.  A case of probable korsakoff's syndrome: a syndrome of frontal lobe and diencephalic structural pathogenesis and a comparison with medial temporal lobe dementias.

Authors:  David R Spiegel; Kheng-Jim Lim
Journal:  Innov Clin Neurosci       Date:  2011-06

2.  The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke's Encephalopathy Presenting at the Emergency Department.

Authors:  Edward C F Wilson; George Stanley; Zulfiquar Mirza
Journal:  Appl Health Econ Health Policy       Date:  2016-04       Impact factor: 2.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.